Citadel Advisors’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-6,406
| Closed | -$352K | – | 14295 |
|
|
2022
Q2 | $352K | Sell |
6,406
-461,403
| -99% | -$24.2M | ﹤0.01% | 9449 |
|
|
2022
Q1 | $15M | Buy |
+467,809
| New | +$13.4M | ﹤0.01% | 2369 |
|
|
2020
Q1 | – | Sell |
-2,690
| Closed | -$37K | – | 10434 |
|
|
2019
Q4 | $37K | Sell |
2,690
-30,778
| -92% | -$402K | ﹤0.01% | 8825 |
|
|
2019
Q3 | $523K | Hold |
33,468
| – | – | ﹤0.01% | 6665 |
|
|
2019
Q2 | $750K | Sell |
33,468
-1
| -0% | -$48 | ﹤0.01% | 6174 |
|
|
2019
Q1 | $2.29M | Sell |
33,469
-12,333
| -27% | -$792K | ﹤0.01% | 4236 |
|
|
2018
Q4 | $2.42M | Buy |
45,802
+1
| +0% | +$64 | ﹤0.01% | 3852 |
|
|
2018
Q3 | $3.11M | Buy |
45,801
+13,715
| +43% | +$1.24M | ﹤0.01% | 3672 |
|
|
2018
Q2 | $3.8M | Buy |
+32,086
| New | +$3.22M | ﹤0.01% | 3144 |
|
|
2017
Q3 | – | Sell |
-275
| Closed | -$13K | – | 8240 |
|
|
2017
Q2 | $13K | Buy |
+275
| New | +$14K | ﹤0.01% | 7358 |
|
|
2016
Q1 | – | Sell |
-607
| Closed | -$365K | – | 8364 |
|
|
2015
Q4 | $365K | Buy |
607
+273
| +82% | +$185K | ﹤0.01% | 4927 |
|
|
2015
Q3 | $274K | Buy |
+334
| New | +$377K | ﹤0.01% | 5703 |
|
Other funds holding SRRA
Citadel Advisors's SRRA Position: Q3 2022 in Review
Citadel Advisors sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q3 2022, closing a stake of 6,406 shares — an estimated $352K sold.
Citadel Advisors first reported a position in SRRA in Q3 2015 and held it in 12 quarters. The position peaked at $15M in Q1 2022. 1 fund tracked by Wall St. Rank holds SRRA as of Q3 2022.
- Citadel Advisors reported no remaining Sierra Oncology, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
- Citadel Advisors sold 6,406 Sierra Oncology, Inc. Common Stock shares in Q3 2022, an estimated $352K.
- Citadel Advisors first reported a position in Sierra Oncology, Inc. Common Stock in Q3 2015 and held it in 12 quarters.
- Citadel Advisors's Sierra Oncology, Inc. Common Stock position peaked at $15M in Q1 2022.
- 1 fund tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q3 2022.
Based on Citadel Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.